Multiple Sclerosis is an autoimmune disease that results in progressive deterioration of the central nervous system. There are approximately 300,000-350,000 individuals in the US and 1 million worldwide who are affected with Multiple Sclerosis. Current therapies are mostly anti-inflammatory, targeting early stages of Multiple Sclerosis. Our proprietary technology would allow us to treat broad stage of MS by targeting specific molecules that are associated with risk and progression of multiple sclerosis.

Tuberous Sclerosis is a genetic disease characterized by developing benign tumors in the brain and other vital organs such as kidneys, heart, eyes, lungs, and skin. There are approximately 50,000 individuals and 1 million worldwide, who suffer TSC. There is currently no specific cure for this disease and the treatment is symptomatic. This would render our product as orphan-drug fro the treatment of TSC. The efficacy of the patented therapeutic method has been independently verified by several medical centers with publications in the New England Journal of Medicine. Our near term goals are to complete combined phase I/II clinical trail for Tuberous Sclerosis and preclinical testing for Multiple Sclerosis drug.

Diabetic nephropathy is the leading cause of end-stage renal disease. Approximately 30% of type 1 diabetics and 10% of type 2 diabetics develop diabetic nephropathy. The current drug treatment has very little effect on preventing progression to end-stage renal disease (ESDR) in diabetic patients. Once patients develop ESDR, the only available treatment is kidney dialysis. Therefore, there are approximately 2.3 million patients in the US without effective treatment, resulting in a significant unmet medical need. The technology licensed by OncoImmune has been proven with strong preclinical data generated from animal models.

R&D Operations We operate in our R & D facilities in Columbus, Ohio and Ann Arbor, Michigan with active collaboration with the University of Michigan and the Ohio State University.